DENIS MEE-LEE: Open Payments
NPI 1730132416 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$99,484 in 298 payments from 14 companies in 2025. Trend: 2023 $91,716 · 2024 $86,507 · 2025 $99,484
Speaker / faculty: $74,021Consulting: $12,500Food & beverage: $6,895Travel & lodging: $5,944Education: $124
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 53 | $26,989 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 60 | $21,250 |
| Otsuka America Pharmaceutical, Inc. | 30 | $17,626 |
| Neurocrine BioSciences, Inc. | 28 | $17,085 |
| ABBVIE INC. | 35 | $14,727 |
| Alkermes, Inc. | 27 | $497 |
| Vanda Pharmaceuticals Inc. | 17 | $340 |
| E.R. Squibb & Sons, L.L.C. | 13 | $298 |
| Lundbeck LLC | 16 | $294 |
| Janssen Pharmaceuticals, Inc | 12 | $215 |
Products named: CAPLYTA, ABILIFY MAINTENA, INGREZZA, VRAYLAR, UZEDY, AUSTEDO XR, ARISTADA, REXULTI.
Industry payments across HI — which companies pay providers there.
